BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37927930)

  • 1. Re-appraisal of the universal definition of tumor rupture among patients with high-risk gastrointestinal stromal tumors.
    Gotohda N; Nishida T; Sato S; Ozaka M; Nakahara Y; Komatsu Y; Kondo M; Cho H; Kurokawa Y; Kitagawa Y
    Ann Gastroenterol Surg; 2023 Nov; 7(6):1021-1031. PubMed ID: 37927930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical importance of tumor rupture in gastrointestinal stromal tumor.
    Nishida T; Gotouda N; Takahashi T; Cao H
    J Dig Dis; 2023 May; ():. PubMed ID: 37210619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study.
    Hølmebakk T; Hompland I; Bjerkehagen B; Stoldt S; Bruland ØS; Hall KS; Boye K
    Ann Surg Oncol; 2018 May; 25(5):1133-1139. PubMed ID: 29435684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological Features and Prognosis of Primary GISTs with Tumor Rupture in the Real World.
    Nishida T; Cho H; Hirota S; Masuzawa T; Chiguchi G; Tsujinaka T;
    Ann Surg Oncol; 2018 Jul; 25(7):1961-1969. PubMed ID: 29752602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the appropriate duration of adjuvant imatinib mesylate treatment for primary gastrointestinal stromal tumors classified according to the strict definition of tumor rupture?
    Lu J; Dai Y; Zheng HL; Xie JW; Wang JB; Lin JX; Chen QY; Cao LL; Lin M; Tu RH; Huang ZN; Lin JL; Li P; Huang CM; Zheng CH
    Medicine (Baltimore); 2019 Jan; 98(3):e14177. PubMed ID: 30653164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy.
    Yanagimoto Y; Takahashi T; Muguruma K; Toyokawa T; Kusanagi H; Omori T; Masuzawa T; Tanaka K; Hirota S; Nishida T
    Gastric Cancer; 2015 Apr; 18(2):426-33. PubMed ID: 24853473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between R1 resection and oncological outcome in resectable gastrointestinal stromal tumors without tumor rupture: A systematic review and meta-analysis.
    Kong M; Liu G; Zhuo H; Xin Y; Chen H; Sheng H; Li L
    Eur J Surg Oncol; 2021 Jul; 47(7):1526-1534. PubMed ID: 33573855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour.
    Hølmebakk T; Bjerkehagen B; Hompland I; Stoldt S; Boye K
    Br J Surg; 2019 Mar; 106(4):419-426. PubMed ID: 30507040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic significance of hemoglobin, albumin, lymphocyte, platelet in gastrointestinal stromal tumors: A propensity matched retrospective cohort study.
    Zhao Z; Yin XN; Wang J; Chen X; Cai ZL; Zhang B
    World J Gastroenterol; 2022 Jul; 28(27):3476-3487. PubMed ID: 36158264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining Tumor Rupture in Gastrointestinal Stromal Tumor.
    Nishida T; Hølmebakk T; Raut CP; Rutkowski P
    Ann Surg Oncol; 2019 Jun; 26(6):1669-1675. PubMed ID: 30868512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.
    Guérin A; Sasane M; Keir CH; Gauthier G; Macalalad AR; Wu EQ; Conley AP
    JAMA Oncol; 2015 Sep; 1(6):797-805. PubMed ID: 26204106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Definition of tumor rupture in gastrointestinal stromal tumor].
    Zhou YB
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):762-768. PubMed ID: 34530556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and external validation of a nomogram for individualized adjuvant imatinib duration for high-risk gastrointestinal stromal tumors: A multicenter retrospective cohort study.
    Liu R; Wu Y; Gong J; Zhao R; Li L; Wan Q; Lian N; Shen X; Xia L; Shen Y; Xiao H; Wu X; Chen Y; Cen Y; Xu X
    Cancer Med; 2022 Aug; 11(16):3093-3105. PubMed ID: 35297216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Prognostic Nomogram for Recurrence-Free Survival of Patients With Primary Gastrointestinal Stromal Tumors After Surgical Resection: Combination of Prognostic Nutritional Index and Basic Variables.
    Li S; Chen D; Li S; Zhao Z; Yang H; Wang D; Zhang Z; Fu W
    Front Oncol; 2020; 10():581855. PubMed ID: 33585198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of tumour rupture risk on the oncological rationale for the surgical treatment choice of gastrointestinal stromal tumours.
    Peparini N
    World J Gastrointest Surg; 2023 Aug; 15(8):1559-1563. PubMed ID: 37701682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal stromal tumors (GIST) related emergencies.
    Sorour MA; Kassem MI; Ghazal Ael-H; El-Riwini MT; Abu Nasr A
    Int J Surg; 2014; 12(4):269-80. PubMed ID: 24530605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib.
    Bang YH; Ryu MH; Kim HD; Lee HE; Kang YK
    Int J Cancer; 2022 Nov; 151(10):1770-1777. PubMed ID: 35678337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor.
    Rutkowski P; Nowecki ZI; Michej W; Debiec-Rychter M; Woźniak A; Limon J; Siedlecki J; Grzesiakowska U; Kakol M; Osuch C; Polkowski M; Głuszek S; Zurawski Z; Ruka W
    Ann Surg Oncol; 2007 Jul; 14(7):2018-27. PubMed ID: 17473953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
    Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
    JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.